MedTrace Logo

YouScript IMPACT Registry

NCT02191358 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2017-03-01

No results posted yet for this study

Summary

This multicenter observational study aims to investigate the benefits of providing pharmacogenetic testing with the YouScript Personalized Prescribing System which includes a clinical decision support tool and individualized pharmacist recommendations to elderly polypharmacy patients who are most at risk of adverse drug events. The YouScript system is unique in identifying drug-gene, and drug-drug-gene interactions that are missed by existing systems, and represent over 35% of significant interaction warnings. Data analysis will assess the impact of recommendations for medication changes on clinical decision making, patient outcomes, and healthcare resource utilization to determine which medications, specialties, or patient segments derive the greatest benefit from this intervention. Data gathered from patients enrolled in this study will be compared to patients matched on key characteristics from Inovalon's MORE2 healthcare database.

Conditions

  • Adverse Drug Events
  • Adverse Drug Reactions
  • Drug Interaction Potentiation
  • Drug Metabolism, Poor, CYP2D6-RELATED
  • Drug Metabolism, Poor, CYP2C19-RELATED
  • Cytochrome P450 Enzyme Deficiency
  • Cytochrome P450 CYP2D6 Enzyme Deficiency
  • Cytochrome P450 CYP2C9 Enzyme Deficiency
  • Cytochrome P450 CYP2C19 Enzyme Deficiency
  • Cytochrome P450 CYP3A Enzyme Deficiency
  • Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant
  • Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant
  • Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant

Sponsors & Collaborators

Principal Investigators

  • Diana Brixner, PhD, RPh · University of Utah

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2015-08-31
Completion
2015-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02191358 on ClinicalTrials.gov